

Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition.



Natural Alternatives International, Inc.

Investor Presentation

November 2022

Nasdaq: NAII

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.

These statements reflect Natural Alternatives International, Inc.'s (the Company's) current views about future events and financial performance based on certain assumptions. They include the Company's intentions, projections, expectations and beliefs about the Company's future financial and operating results, including management's goals for future operations, industry performance, characteristics and opportunities, effectiveness of distribution channels and customers.

For this purpose, any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. These statements speak only as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially. This presentation is qualified by the risks and other information set forth in the Company's Form 10-K filed with the SEC.

These forward-looking statements are made only as of the date hereof, and Natural Alternatives undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.



Regulation G

In addition, in order to assist you with period-over-period comparisons on a consistent and comparable basis, our presentation includes certain non-US GAAP information. This information excludes certain non-cash expenses, certain cash income and expense items related to our foreign currency hedging program and taxes, as well as certain non-recurring income and expense items related to the gain on sale of our Company's former headquarters, and the one-time write-off of accounts receivable and inventory related to a former customer.

This non-US GAAP information may include non-US GAAP financial measures within the meaning of Regulation G. These non-US GAAP measures should not be considered as a substitute for any measure derived in accordance with US GAAP. The non-US GAAP information may also be inconsistent with the manner in which similar measures are derived or used by other companies. Management uses such non-US GAAP information for financial and operational decision-making purposes and as a means to evaluate period-over-period comparisons and in forecasting the Company's business going forward.

Management believes that the presentation of such non-US GAAP information, when considered in conjunction with the most directly comparable US GAAP information, provides additional useful comparative information for investors in their assessment of the underlying performance of the Company's business with regard to these items. The Company has provided reconciliations of such non-US GAAP financial measures to the most directly comparable financial measures prepared in accordance with US GAAP. The reconciliations are included in this presentation.



Company Snapshot

NAII is the only pure-play public company that offers global formulation and manufacturing of customized nutritional supplements along with marketing branded and patented products



Contract Manufacturing

We provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements and health care products to consumers



Patent & Trademark Licensing

In-house brand leveraging our proprietary ingredients CarnoSyn[®] and SR CarnoSyn[®] targeting sports nutrition, wellness, and healthy aging markets



Headquarters: Carlsbad, CA Founded in 1980 Nasdaq: NAII TTM Revenue*: \$175.8M

Market Capitalization: \$52.0M (as of 11/08/2022)



Company Strengths

Multi-Continent Contract Manufacturing Facilities

- Custom product formulation
- State-of-the-art manufacturing facilities
- Broad material acquisition & analysis
- Certified in-house laboratory capabilities
- Multiple packaging configuration capabilities





In-House Brand Leveraging Of Our Proprietary Ingredients

- CarnoSyn[®] and SR CarnoSyn[®] targeting sports nutrition, wellness, and healthy aging markets
 - Direct-to-consumer launched June 2020



Company Strengths

Growth Drivers From Organic Initiatives And Complementary Acquisitions

- Expand existing customer products, base and channels
- Expand in-house brands
- Complementary acquisitions





Solid Cash Flows And Strong Balance Sheet To Support Growth Objectives

- TTM* net sales of \$175.8 million
- Working Capital of \$47.6 million at 9/30/2022



Executive Management Team



Mark A. LeDoux CEO and Chairman of the Board of Directors

Mr. LeDoux founded Natural Alternatives International (NAI) in 1980. With over 45 years of experience since joining the nutritional supplements industry in 1975, Mr. LeDoux is considered a highly regarded leader and spokesperson for our industry – making him one of the longest serving active executives in the nutritional supplements industry. As Chairman of the Board of Directors of the prestigious Natural Products Association (NPA) based in Washington DC, where he has been a member since 1980, Mr. LeDoux represents NAI's ongoing commitment to industry and government affairs, adherence to a strong code of ethics, and continuing support in the legislative, regulatory and public affairs arenas.

He was former Chairman and Board member of the esteemed Council for Responsible Nutrition (CRN) and Founding Chairman of CRN International. LeDoux also serves on the Nutrition Industry Association-west (NIA) Board and is a recognized participant of the Codex Alimentarius Commission, the United Nations' food and dietary supplement standard-setting body under the joint supervision of its Food and Agriculture Organization and World Health Organization.

In addition, LeDoux currently serves as Chairman of the Board of Selectmen in his hometown of Hollis, New Hampshire. He is President of the Marie A. LeDoux Charitable Foundation and a current member of the Young Presidents Organization Graduates. A graduate of the Thomas Jefferson School of Law, Mr. LeDoux received his bachelor's degree from the University of Oklahoma, where he graduated with honors. He is also a graduate of Stanford University's Program for Small Business Executives.



Executive Management Team



Kenneth E. Wolf President and Chief Operating Officer

Mr. Wolf joined NAI in February 2008 as Chief Financial Officer, was promoted to Chief Operating Officer in June 2010 and has served as NAI's President since October 2015. Mr. Wolf is responsible for design and implementation of NAI's long-term strategic plans and oversight of all areas within the company. He possesses over 26 years of senior financial management experience in both publicly traded and privately held companies, with the prior 21 years associated with consumer products manufacturing companies. Mr. Wolf received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration – Accounting from California State University in Fresno, California.



Michael E. Fortin Chief Financial Officer

Mr. Fortin joined NAI in April 2008 as Director of Accounting and SEC Reporting and earned his appointment to Chief Financial Officer in October 2015. With over 20 years of accounting and finance experience working in Big 4 public accounting and private industry, Mr. Fortin is a steadfast, strategic leader responsible for driving financial and business results. Mr. Fortin received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration-Accounting from San Diego State University, California.



Overview – Capabilities

Global Production

- Up to 17 million capsules and 11 million tablets daily capacity
- Up to 500,000 bottles finished product daily capacity
- Highly sophisticated in-house laboratories
- Warehousing 7,500+ pallet capacity

Regulatory

- Full Label Panel Testing and Quality Assurance
- DSHEA and FDA compliant labeling
- International product registration support


Intellectual Property

- 11 US Patents
- 9 corresponding non-US patents registered throughout North America, Europe, Asia
- 11 US trademark registrations
- 34 foreign trademark registrations, covering 41 countries

Sales & Marketing

- Experienced global sales and marketing team
- Strong brand recognition in sports nutrition
- World class customer service





Overview – Contract Manufacturing

Product Formulation

- Custom formulations
- In-house science teams
- Clinical study design and support •
- In-house product stability testing capabilities

Material Acquisition and Analysis


- Global raw material sourcing expertise
- Transparency and tracking of material sources
- Extensive vendor certification program


Facilities

- Vista, CA USA (162,000 SF manufacturing)
- Carlsbad, CA USA (21,000 SF office space) •
- Carlsbad, CA USA (54,000 SF manufacturing)
- Manno, Switzerland (127,000 SF manufacturing)

Forms

- Capsules
- Chewables







Overview – Patent & Trademark Licensing

In-house brand expansion leveraging our proprietary ingredients: CarnoSyn[®] and SR CarnoSyn[®] beta-alanine.







Please visit websites by clicking on logo.

المعنى Natural Alternatives NAL بن International, Inc.

Sports Nutrition

- Enhance athletic performance
- Build muscle and reach peak sustainable performance
- New sustained release form of CarnoSyn[®] remains in the body longer
- New Dietary Ingredient (NDI) Status with the FDA
- Self-Affirmed GRAS Status
- The Natural Products Association 2019 Novel Ingredient and Science Award Recipient
- 2019 NutraIngredients Sports Nutrition Ingredient of the Year

Health & Wellness

- Improves everyday muscle capacity and health
- "Wellness" and "Healthy Aging" products
- Specifically formulated for the health care practitioner market
- Self-Affirmed GRAS Status

Direct-to-Consumer

- Immunity boost, mental clarity, total body wellness
- Launched June 2020
- Sold exclusively on Amazon
- Provides platform for additional DTC products

Worldwide Operations and Market Reach

NAI's global footprint and scope facilitates greater opportunities and more dynamic client engagement



International, Inc.

12

NAI US Facilities Tour





Accreditations

Industry leading accreditations and certification demonstrate our commitment to quality and are a strong barrier to entry

Domestic (NAI)

Good Manufacturing Practices (cGMPs) (*21 CFR 111*) compliant – FDA Inspected; Zero 483 observations

Therapeutic Goods Administration (TGA) GMP Compliance certified

Health Canada (NNHPD) GMP Compliance – Foreign Site Reference Number issued

NSF International – GMP certified (21 CFR 111 & 21 CFR 117)

NSF International – GMP for Sport certified

Certified Organic (Natural Food Certifiers)

Supplement Safety & Compliance Initiative (SSCI) certification

International (NAIE)

SwissMedic GMP certified – site registered and licensed

Laboratorio cantonale - inspected and certified under Official Food Law Enforcement Authority

Informed Choice/Informed Sport (LGC) certified

Institut Fresenius (SGS) GMP Certified

SGS Hazard Analysis and Critical Control Point (HACCP) Codex Alimentarius Certified





Industry Trends

We will benefit from growing consumer interest in health and wellness




Growing vitamin, mineral, & supplement ("VMS") industries:

- USA Dietary supplement market is estimated at US \$60 billion in 2022 and projected to grow at a 5.2% CAGR through 2028²
- Global Dietary supplement market is estimated at US \$226 billion in 2022 and projected to grow at an 5.9% CAGR through 2028²



US Supplement Market Forecast

A new level of demand has been established with an estimated CAGR of 5.2%; Supplement industry on track to pass \$59B in 2022 and grow to \$80B+ by 2028



Others



Global Supplement Market Forecast

Global trend is matching US trend Global market growth expected at a CAGR of 5.9% growth to \$319B in revenue by 2028.











Financial Performance and Growth Objectives

Historical Revenue and EBITDA

Sales in FY21 increased primarily due to higher sales from a majority of our distribution channels worldwide, including higher sales of immune and wellness products that appears to be driven by consumers taking a more active role in their health and wellness as a result of the COVID-19 pandemic. We also added new products from existing customers and new products from new customer acquisitions.








*See Non-US GAAP Adjusted EBITDA reconciliation on slide 29 **Trailing 12 Months (TTM) – Includes October 2021 through September 2022 ***Compound Annual Growth Rate is FY17 to FY23

Historical Sales By Channel





**Trailing 12 Months (TTM) – Includes October 2021 through September 2022

Objectives & Growth Drivers

• Fiscal 2023 and Beyond Targeted Growth Objectives:

- ✓ Achieve \$210 million to \$250 million revenue run-rate in the next 3 years with double digit Adjusted EBITDA margins
- ✓ Target sales growth rate of 5-10% per year
- Pursue complimentary accretive acquisitions generating \$10-\$50 million in sales over the next 3 years



Acquisition Strategy



Channels

Health Care Practitioner Multi-Level Marketer Direct-to-Consumer Specialty Retail Drug Store Mass



Markets

Vitamins, Minerals, Supplements Personal Care Over-the-Counter



Verticals

Wellness Brands High Value Ingredient Suppliers Contract Manufacturers Value-Add Distributors



Forms

Capsules/Tablets, Powders Liquids, Lotions, Creams Chewable Wafers, Gummy/Soft-Chew Effervescent, Strips, Patches Probiotics



Investment Thesis

- As of November 4, 2022, global capacity utilization of ~60%
 - New high-capacity blender came online January 2022 in our Vista, CA facility increasing our overall product blending capacity in the USA by approximately 30%
 - Acquisition of new Manufacturing and Warehouse Facility in August 2021:
 - To be retrofitted to become a dedicated high-volume powder blending and packaging facility by middle of fiscal year 2023
 - Facility expected to provide substantially more warehouse, blending, and powder packaging capacity
 - Positioned to take advantage of current opportunities as well as new potential opportunities in the growing market of whole-food-based meal replacement powders as well as other powder product types
- As utilization increases, fixed costs remain relatively flat and profit margins improve
- Solid financial condition and ability to generate strong cash flow will allow us to increase capacity and or seek acquisition opportunities
- As of September 30, 2022, trading at under 5.03x EV/Adjusted EBITDA



Investor Information

Stock Symbol: NASDAQ: NAII Company website: <u>http://www.nai-online.com</u>

Company Headquarters:

1535 Faraday Avenue Carlsbad, CA 92008

Investor Relations Contacts

Michael Fortin Chief Financial Officer 760-736-7700 investor@nai-online.com











Appendix

Investor Relations Info

Historical Segment Performance

	Fiscal Year ended June 30,						Trailing 12 Months*		
		2020		2021		2022		(Unaudited)	
Revenue				1.1.1				1.00	
Private Label Contract Manufacturing	\$	106,291	\$	164,310	\$	154,798	\$	162,979	
Patent & Trademark Licensing		12,585		14,210		16,168		12,774	
Total Revenue	\$	118,876	\$	178,520	\$	170,966	\$	175,753	
Income (Loss) from Operations									
Private Label Contract Manufacturing	\$	4,030	\$	17,744	\$	15,667	\$	15,207	
Patent & Trademark Licensing		2,508		4,442		6,780		4,492	
Income from operations of reportable segments		6,538		22,186		22,447		19,699	
Corporate expense not allocated to segments		(8,047)		(8,514)		(8,768)		(8,706	
(Loss) Income from Operations	\$	(1,509)	\$	13,672	\$	13,679	\$	10,993	
Revenue as a %									
Private Label Contract Manufacturing		89.4%		92.0%		90.5%		92.7%	
Patent & Trademark Licensing		10.6%		8.0%		9.5%		7.3%	
Operating Margins									
Private Label Contract Manufacturing		3.8%		10.8%		10.1%		9.3%	
Patent & Trademark Licensing		19.9%		31.3%		41.9%		35.2%	
Income from Operations of reportable segments		5.5%		12.4%		13.1%		11.2%	
(Loss) Income from Operations		-1.3%		7.7%		8.0%		6.3%	



Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited) Three Months Ended					
	20)22	8 T	2021	
NET SALES	\$	43,127	100.0%	38,340	- 100.0%
Cost of goods sold		37,756	87.5%	30,059	78.4%
Gross profit		5,371	12.5%	8,281	21.6%
Selling, general & administrative expenses		3,829	8.9%	4,053	10.6%
INCOME FROM OPERATIONS		1,542	3.6%	4,228	11.0%
Other income, net		(224)	-0.5%	(26)	-0.1%
INCOME BEFORE TAXES		1,318	3.1%	4,202	11.0%
Income tax expense	_	265		946	
NET INCOME	\$	1,053		\$ 3,256	- L.
NET INCOME PER COMMON SHARE:					
Basic:		\$0.18		\$0.52	
Diluted:		\$0.18		\$0.51	-
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic		5,920		6,288	
Diluted		5,943		6,351	



Condensed Consolidated Balance Sheets

NATURAL ALTERNATIVES INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

. . . .

	(unaudited)			
	September 30,	June 30,		
	2022	2022		
ASSETS		والمتعالم المحاد الم		
Cash and cash equivalents	\$12,341	\$21,833		
Accounts receivable, net	14,822	17,422		
Inventories, net	39,990	32,475		
Other current assets	7,251	5,016		
Total current assets	74,404	76,746		
Property and equipment, net	51,384	44,573		
Operating lease right-of-use assets	21,136	21,701		
Other noncurrent assets, net	2,644	2,983		
Total Assets	\$149,568	\$146,003		
LIABILITIES AND STOCKHOLDERS' EQUITY				
Accounts payable and accrued liabilities	25,441	25,641		
Credit Line	3,400	-		
Mortgage note payable	9,727	9,795		
Long-term liability - operating leases	21,144	22,047		
Total Liabilities	59,712	57,483		
Stockholders' Equity	89,856	88,520		
Total Liabilities and Stockholders' Equity	\$149,568	\$146,003		



Adjusted EBITDA Reconciliation (Non-US GAAP)

Natural Alternatives International, Inc. Adjusted EBITDA – Non – US GAAP Reconciliation							
(In Thousands) (Unaudited)	FY17	FY18	FY19	FY20	FY21	FY22	Trailing 12 Months*
Net Income (Loss)	\$7,235	\$5,051	\$6,541	(\$1,645)	\$10,768	\$10,712	\$8,509
Interest Income	(459)	(1,085)	(1,868)	(177)	(1)		(4)
Interest Expense	(10)	(1,000)	(1,000)	66	118	83	
Taxes	2,876	5,562	1,412	(93)	1,358	2,947	
Depreciation & Amortization	2,384	2,908	3,465	3,959	4,338	4,165	4,033
Traditional EBITDA	\$12,039	\$12,445	\$9,579	\$2,110	\$16,581	\$17,907	\$14,950
Non-cash Compensation	1,032	1,334	1,672	1,712	1,430	9 <mark>6</mark> 8	981
Non-cash Sales Discount		898	82		_		_
Forward Pts in Revenue	-	_	_	(863)	(518)	(389)	(387)
Acquisition Costs	-	117	512	30	—	_	_
Foreign Exchange (Gain) Loss	28	(18)	(148)	320	1,408	(118)	23
One Time Gain on Building	-	—	_	_	_	_	_
One Time Kaged Muscle Adjustment**				4,288	(696)		
Adjusted EBITDA	\$13,099	\$14,776	\$11,697	\$7,597	\$18,205	\$18,368	\$15,567

*Trailing 12 Months – Includes October 2021 through September 2022



**Represents an inventory and accounts receivable reserve and subsequent recoveries related to a former customer. Due to the nature of our business and the underlying circumstances of this charge, we consider this a non-recurring item and is not representative of our ongoing operational performance.



Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition.



Thank You

www.nai-online.com

Nasdaq: NAII